Daiichi Sankyo plans to close its research subsidiary, U3 Pharma GmbH in Germany. U3, with about 40 employees, is engaged in research and development work on antibody targeting for cancer treatments. It will transfer its current research and development tasks to the company’s biologics function in Tokyo.

Daiichi Sankyo said it intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed, and the company has decided to concentrate core research functions of Daiichi Sankyo Group in the future. Daiichi Sankyo will provide a more detailed update on the impact of this announcement with its FY 2015 business results at a later date.

Source: Daiichi Sankyo